Literature DB >> 17938883

Pro-atrial natriuretic peptide and pro-vasopressin to predict severity and prognosis in community-acquired pneumonia: results from the German competence network CAPNETZ.

Stefan Krüger1, Jana Papassotiriou, Reinhard Marre, Klaus Richter, Christian Schumann, Heike von Baum, Nils G Morgenthaler, Norbert Suttorp, Tobias Welte.   

Abstract

OBJECTIVE: Community acquired pneumonia (CAP) is the most important clinical infection. Therefore, the CAP competence network CAPNETZ was instituted in Germany. The aim of this substudy was to evaluate the value of pro-atrial natriuretic peptide (MR-proANP) and pro-vasopressin (CT-proAVP) for severity assessment and outcome prediction in CAP.
DESIGN: Prospective observational study.
SETTING: German CAP competence network CAPNETZ.
METHODS: We enrolled 589 patients (age 61+/-18 years, 46% female) with proven CAP. MR-proANP, CT-proAVP, C-reactive protein (CRP), procalcitonin (PCT) and CRB-65 score were determined on admission.
RESULTS: MR-proANP, CT-proAVP and PCT levels, but not CRP, increased with increasing severity of CAP, classified according to the CRB-65 score. In patients who died during 28-day follow-up, median MR-proANP and CT-proAVP levels (respectively 237.0 vs. 93.5 pmol/l and 44.2 vs. 12.4 pmol/l, each p<0.0001) were significantly higher than in survivors. In receiver operating characteristic (ROC) analysis for survival, the area under the curve (AUC) values for CT-proAVP (0.86, 95% CI 0.83-0.89) and MR-proANP (0.76, 95% CI 0.72-0.80) were similar to the AUC of CRB-65 (0.73, 95% CI 0.70-0.77). In multivariable Cox proportional-hazards regression analyses including MR-proANP/CT-proAVP, coexisting illnesses and CRB-65, increased MR-proANP and CT-proAVP concentrations were the strongest predictors of mortality.
CONCLUSIONS: MR-proANP and CT-proAVP are useful new biomarkers for the risk stratification of CAP patients. They are significantly lower in CAP survivors and correlate with the severity of the disease measured by CRB-65 score.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17938883     DOI: 10.1007/s00134-007-0895-5

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  36 in total

1.  Copeptin and arginine vasopressin concentrations in critically ill patients.

Authors:  Stefan Jochberger; Nils G Morgenthaler; Viktoria D Mayr; Günter Luckner; Volker Wenzel; Hanno Ulmer; Siegfried Schwarz; Walter R Hasibeder; Barbara E Friesenecker; Martin W Dünser
Journal:  J Clin Endocrinol Metab       Date:  2006-08-29       Impact factor: 5.958

2.  Assessment of pneumonia severity: a European perspective.

Authors:  S Ewig; A Torres; M Woodhead
Journal:  Eur Respir J       Date:  2006-01       Impact factor: 16.671

3.  Combining information from prognostic scoring tools for CAP: an American view on how to get the best of all worlds.

Authors:  M S Niederman; C Feldman; G A Richards
Journal:  Eur Respir J       Date:  2006-01       Impact factor: 16.671

4.  Serum vasopressin concentrations in critically ill patients.

Authors:  Stefan Jochberger; Viktoria D Mayr; Günter Luckner; Volker Wenzel; Hanno Ulmer; Stefan Schmid; Hans Knotzer; Werner Pajk; Walter Hasibeder; Barbara Friesenecker; Andreas J Mayr; Martin W Dünser
Journal:  Crit Care Med       Date:  2006-02       Impact factor: 7.598

5.  Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis.

Authors:  Martina Brueckmann; Guenter Huhle; Siegfried Lang; Karl K Haase; Thomas Bertsch; Christel Weiss; Jens J Kaden; Christian Putensen; Martin Borggrefe; Ursula Hoffmann
Journal:  Circulation       Date:  2005-07-18       Impact factor: 29.690

6.  Procalcitonin as a diagnostic tool in lower respiratory tract infections and tuberculosis.

Authors:  A Polzin; M Pletz; R Erbes; M Raffenberg; H Mauch; S Wagner; G Arndt; H Lode
Journal:  Eur Respir J       Date:  2003-06       Impact factor: 16.671

7.  Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index.

Authors:  Mar Masiá; Félix Gutiérrez; Conrado Shum; Sergio Padilla; Juan Carlos Navarro; Emilio Flores; Ildefonso Hernández
Journal:  Chest       Date:  2005-10       Impact factor: 9.410

8.  Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: impact of interleukin-6 and sepsis-associated left ventricular dysfunction.

Authors:  Rochus Witthaut; Christian Busch; Peter Fraunberger; Autar Walli; Dietrich Seidel; Günter Pilz; Ralph Stuttmann; Norbert Speichermann; Ljifane Verner; Karl Werdan
Journal:  Intensive Care Med       Date:  2003-08-12       Impact factor: 17.440

9.  The confounding effects of age, gender, serum creatinine, and electrolyte concentrations on plasma B-type natriuretic peptide concentrations in critically ill patients.

Authors:  Anthony S McLean; Stephen J Huang; Marek Nalos; Benjamin Tang; Donald E Stewart
Journal:  Crit Care Med       Date:  2003-11       Impact factor: 7.598

10.  Pro-atrial natriuretic peptide is a prognostic marker in sepsis, similar to the APACHE II score: an observational study.

Authors:  Nils G Morgenthaler; Joachim Struck; Mirjam Christ-Crain; Andreas Bergmann; Beat Müller
Journal:  Crit Care       Date:  2004-12-17       Impact factor: 9.097

View more
  20 in total

1.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

2.  Severity of illness assessment for managing community-acquired pneumonia.

Authors:  Jordi Rello; Alejandro Rodriguez
Journal:  Intensive Care Med       Date:  2007-10-16       Impact factor: 17.440

Review 3.  Year in review in Intensive Care Medicine, 2007. II. Haemodynamics, pneumonia, infections and sepsis, invasive and non-invasive mechanical ventilation, acute respiratory distress syndrome.

Authors:  Massimo Antonelli; Elie Azoulay; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; Daniel De Backer; François Lemaire; Herwig Gerlach; Johan Groeneveld; Goran Hedenstierna; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Philipp Metnitz; Jerme Pugin; Jan Wernerman; Haibo Zhang
Journal:  Intensive Care Med       Date:  2008-01-31       Impact factor: 17.440

4.  Sophisticated biomarkers for community-acquired pneumonia severity asessment: gadgets or useful tools?

Authors:  François G Brivet; Frédéric M Jacobs; Dominique Prat; Bogdan D Grigoriu
Journal:  Intensive Care Med       Date:  2008-01-08       Impact factor: 17.440

5.  Increased levels of pro-AVP and pro-ADM in septic shock patients: what could it mean?

Authors:  Antoine Roch
Journal:  Intensive Care Med       Date:  2009-08-07       Impact factor: 17.440

6.  Assessment of pro-vasopressin and pro-adrenomedullin as predictors of 28-day mortality in septic shock patients.

Authors:  Caroline Guignant; Nicolas Voirin; Fabienne Venet; Françoise Poitevin; Christophe Malcus; Julien Bohé; Alain Lepape; Guillaume Monneret
Journal:  Intensive Care Med       Date:  2009-08-07       Impact factor: 17.440

7.  Hospital admission decision for patients with community-acquired pneumonia.

Authors:  Stefano Aliberti; Paola Faverio; Francesco Blasi
Journal:  Curr Infect Dis Rep       Date:  2013-04       Impact factor: 3.725

Review 8.  Defining and predicting severe community-acquired pneumonia.

Authors:  Samuel M Brown; Nathan C Dean
Journal:  Curr Opin Infect Dis       Date:  2010-04       Impact factor: 4.915

Review 9.  The role of biomarkers in community-acquired pneumonia: predicting mortality and response to adjunctive therapy.

Authors:  Jean-Paul Mira; Adeline Max; Pierre-Regis Burgel
Journal:  Crit Care       Date:  2008-11-26       Impact factor: 9.097

Review 10.  Biomarkers: a definite plus in pneumonia.

Authors:  Hanssa Summah; Jie-Ming Qu
Journal:  Mediators Inflamm       Date:  2009       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.